©TheCanadian Journal ofUrology™: International Supplement, April 2014
12
Thechanging landscapeofadvancedandcastrationresistantprostatecancer: latestscienceandreviseddefinitions
18.Fowler JE, Jr.,WhitmoreWF, Jr. Considerations for the use of
testosterone with systemic chemotherapy in prostatic cancer.
Cancer
1982;49(7):1373-1377.
19.Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3)
prostatecancer: refining theconcept.
Urology
1995;46(2):142-148.
20.ChenY, Scher HI. Prostate cancer in 2011: Hitting old targets
betterand identifyingnew targets.
NatRevClinOncol
2012;9(2):
70-72.
21.ScherHI,MorrisMJ,KellyWK,SchwartzLH,HellerG.Prostate
cancerclinical trialendpoints: “RECIST”ingastepbackwards.
ClinCancerRes
2005;11(14):5223-5232.
22.Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick
MI. Reassessment of the definition of castrate levels of
testosterone: implications forclinicaldecisionmaking.
Urology
2000;56(6):1021-1024.
23.MoroteJ,OrsolaA,PlanasJetal.Redefiningclinicallysignificant
castration levels in patients with prostate cancer receiving
continuousandrogendeprivationtherapy.
JUrol
2007;178(4Pt1):
1290-1295.
24.Saad F, Hotte SJ. Guidelines for themanagement of castrate-
resistant prostate cancer.
CanUrolAssoc J
2010;4(6):380-384.
25.Cookson MS, Roth BJ, Dahm P et al. Castration-Resistant
ProstateCancer:AUAGuideline.
JUrol
2013;190(2):429-438.
26.Scher HI, Halabi S, Tannock I et al. Design and end points
of clinical trials for patients with progressive prostate cancer
and castrate levels of testosterone: recommendations of the
ProstateCancerClinicalTrialsWorkingGroup.
JClinOncol
2008;
26(7):1148-1159.
27.Centenera MM, Harris JM, Tilley WD, Butler LM. The
contribution of different androgen receptor domains to
receptordimerizationandsignaling.
MolEndocrinol
2008;22(11):
2373-2382.
28.GelmannEP.Molecularbiologyof theandrogenreceptor.
JClin
Oncol
2002;20(13): 3001-3015.
29.YuanX,CaiC,ChenS,YuZ,BalkSP.Androgenreceptorfunctions
in castration-resistant prostate cancer and mechanisms of
resistance tonew agents targeting the androgen axis.
Oncogene
2013. Epubaheadofprint.
30.Glass CK, Rosenfeld MG. The coregulator exchange in
transcriptional functions of nuclear receptors.
GenesDev
2000;
14(2):121-141.
31.HeinleinCA, ChangC.Androgen receptor inprostate cancer.
EndocrRev
2004;25(2):276-308.
32.BluemnEG,NelsonPS. Theandrogen/androgen receptoraxis
inprostate cancer.
CurrOpinOncol
2012;24(3):251-257.
33.GregoryCW, JohnsonRT Jr,Mohler JL, FrenchFS,WilsonEM.
Androgen receptor stabilization in recurrent prostate cancer is
associatedwith hypersensitivity to low androgen.
Cancer Res
2001;61(7):2892-2898.
34.Wright JL, KwonEM,OstranderEAet al. Expressionof SLCO
transport genes in castration-resistant prostate cancer and
impact of genetic variation in SLCO1B3 and SLCO2B1 on
prostatecanceroutcomes.
CancerEpidemiolBiomarkersPrev
2011;
20(4): 619-627.
35.Yang M, Xie W, Mostaghel E et al. SLCO2B1 and SLCO1B3
may determine time to progression for patients receiving
androgendeprivation therapy forprostate cancer.
JClinOncol
2011;29(18):2565-2573.
36.KoivistoP,KononenJ,PalmbergCetal.Androgenreceptorgene
amplification: a possible molecular mechanism for androgen
deprivation therapy failure inprostatecancer.
CancerRes
1997;
57(2):314-319.
37.VisakorpiT,HyytinenE,KoivistoPetal. Invivoamplificationof
theandrogenreceptorgeneandprogressionofhumanprostate
cancer.
NatGenet
1995;9(4):401-406.
38.Labrie F, Belanger A, Dupont A et al. Science behind total
androgen blockade: from gene to combination therapy.
Clin
InvestMed
1993;16(6):475-492.
39.AdachiM,TakayanagiR,TomuraAetal.Androgen-insensitivity
syndromeas apossible coactivatordisease.
NEngl JMed
2000;
343(12):856-862.
40.GregoryCW,HeB, JohnsonRTetal.Amechanism forandrogen
receptor-mediated prostate cancer recurrence after androgen
deprivation therapy.
CancerRes
2001;61(11):4315-4319.
41.Buchanan G, Greenberg NM, Scher HI et al. Collocation of
androgenreceptorgenemutations inprostatecancer.
ClinCancer
Res
2001;7(5):1273-1281.
42.Gottlieb B, Lehvaslaiho H, Beitel LK et al. The Androgen
ReceptorGeneMutationsDatabase.
NucleicAcidsRes
1998;26(1):
234-238.
43.Marcelli M, Ittmann M, Mariani S et al. Androgen receptor
mutations inprostate cancer.
CancerRes
2000;60(4):944-949.
44.Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the
androgen-receptor gene inmetastatic androgen-independent
prostate cancer.
NEngl JMed
1995;332(21):1393-1398.
45.CaiC,HeHH,ChenSetal.Androgenreceptorgeneexpression
in prostate cancer is directly suppressed by the androgen
receptor through recruitment of lysine-specificdemethylase1.
CancerCell
2011;20(4):457-471.
46.ChangYM,BaiL,LiuSetal.Srcfamilykinaseoncogenicpotential
and pathways in prostate cancer as revealed by AZD0530.
Oncogene
2008;27(49):6365-6375.
47.Craft N, Shostak Y, CareyM, Sawyers CL. Amechanism for
hormone-independent prostate cancer throughmodulationof
androgenreceptorsignalingby theHER-2/neu tyrosinekinase.
NatMed
1999;5(3):280-285.
48.Culig Z, HobischA, Cronauer MV et al. Androgen receptor
activation in prostatic tumor cell lines by insulin-like growth
factor-I, keratinocyte growth factor, and epidermal growth
factor.
CancerRes
1994;54(20):5474-5478.
49.Dehm SM, Schmidt LJ, HeemersHV, Vessella RL, Tindall DJ.
Splicing of a novel androgen receptor exon generates a
constitutivelyactiveandrogen receptor thatmediatesprostate
cancer therapy resistance.
CancerRes
2008;68(13):5469-5477.
50.GraffJR,KonicekBW,McNultyAMetal. IncreasedAKTactivity
contributes to prostate cancer progression by dramatically
acceleratingprostate tumor growth anddiminishingp27Kip1
expression.
J Biol Chem
2000;275(32):24500-24505.
51.NelsonEC,EvansCP,MackPC,Devere-WhiteRW,LaraPN Jr.
InhibitionofAktpathways in the treatment ofprostate cancer.
ProstateCancerProstaticDis
2007;10(4):331-339.
52.QiuY, Ravi L, KungHJ. Requirement of ErbB2 for signalling
by interleukin-6 in prostate carcinoma cells.
Nature
1998;393
(6680):83-85.
53.SharmaA, YeowWS, ErtelA et al. The retinoblastoma tumor
suppressor controls androgen signaling and human prostate
cancer progression.
JClin Invest
2010;120(12):4478-4492.
54.Sun S, SprengerCC, VessellaRLet al. Castration resistance in
humanprostate cancer is conferred by a frequently occurring
androgen receptor splice variant.
J Clin Invest
2010;120(8):
2715-2730.
55.Wang Q, Li W, Zhang Y et al. Androgen receptor regulates
a distinct transcription program in androgen-independent
prostate cancer.
Cell
2009;138(2):245-256.
56.Watson PA, Chen YF, Balbas MD et al. Constitutively active
androgen receptor splice variants expressed in castration-
resistantprostatecancer require full-lengthandrogen receptor.
ProcNatlAcadSciUSA
2010;107(39):16759-16765.
57.YehS,LinHK,KangHYet al. FromHER2/Neu signal cascade
to androgen receptor and its coactivators: a novel pathway
by induction of androgen target genes throughMAP kinase
in prostate cancer cells.
Proc Natl Acad Sci U S A
1999;96(10):
5458-5463.
58.ColombelM,SymmansF,GilSetal.Detectionof theapoptosis-
suppressing oncoprotein bc1-2 in hormone-refractory human
prostate cancers.
Am J Pathol
1993;143(2):390-400.
